HPV, p16 Status May Affect Prognosis in HNSCC

Share this content:
Among patients suffering post-radiation or chemoradiation locoregional HNSCC recurrence, those with HPV-positive disease may have better survival rates.
Among patients suffering post-radiation or chemoradiation locoregional HNSCC recurrence, those with HPV-positive disease may have better survival rates.

Among patients suffering post-radiation or chemoradiation locoregional head and neck squamous cell carcinoma (HNSCC) recurrence, those with human papillomavirus (HPV)-positive disease have better survival rates, while those with oral cavity carcinomas fared worse, according to a single-institution cohort study of 1000 patients published in JAMA Oncology.1

Tumor expression of the p16 (cyclin-dependent kinase inhibitor 2A) suppression protein also had longer survival times prior to metastasis, and a subset of patients with solitary oligometastasis survived longer than other patients with metastatic HNSCC.

Between 15% and 50% of patients with HNSCC suffer tumor recurrence.

To assess patterns and correlates of treatment failure and patient survival following HNSCC recurrence among patients who had undergone intensity-modulated radiotherapy (IMRT) with or without concurrent chemotherapy, the authors conducted this single-institution cohort study.

Among 186 women and 814 men treated for stage III to IVB HNSCC between 2001 and 2013, locoregional failure rates were higher for patients with oral cavity carcinomas than those with oropharyngeal carcinomas (hazard ratio [HR] 5.2; 95% CI, 3.1-8.6; P < .001) or tumor subsites.

Oral cavity carcinomas were also associated with worse survival following metastasis to distant sites (HR 3.66; 95% CI, 1.98-6.80; P < .001).

“Patients with oropharyngeal carcinoma positive for human papillomavirus or p16 lived longer after locoregional failure compared with patients with oropharyngeal carcinoma negative for human papillomavirus or p16” prior to metastasis, the authors noted. Median survival was 36.5 months vs 13.6 months (P = .007) but this association was not found among patients suffering distant metastasis.

RELATED: PD-L1 Expression Predicts Response to PD-1/PD-L1 Inhibition

“Salvage surgery was associated with improved overall survival [OS] following locoregional failure (HR 0.51; 95% CI, 0.34-0.77; P = .001); oligometastatic disease (1 vs ≥2 lesions; HR 0.32; 95% CI, 0.16-0.63; P = .001) was associated with improved overall survival following distant metastasis,” they concluded. 

Reference

  1. Leeman JE, Li JG, Pei X, et al. Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol. 2017 May 25. doi: 10.1001/jamaoncol.2017.0973 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters